Doxorubicin liposomal - GP Pharm

Drug Profile

Doxorubicin liposomal - GP Pharm

Alternative Names: Sarcodoxome

Latest Information Update: 04 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GP Pharm
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Soft tissue sarcoma

Most Recent Events

  • 04 Sep 2018 No development reported - Phase-II for Soft tissue sarcoma (First-line therapy, In the elderly) in Spain (IV)
  • 14 Dec 2015 Phase II development is ongoing Spain
  • 21 Dec 2006 GP Pharm's liposomal doxorubicin has received Orphan Drug Status for Soft Tissue Sarcoma in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top